Portfolio companies news
-
17 August 2015
Tobira Therapeutics, Inc. (NASDAQ: TBRA), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel treatments for liver and inflammatory diseases, announced today the enrollment of the first patient into the Phase 2a ORION study.
-
13 August 2015
Neothetics Reports Second Quarter 2015 Financial Results
Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today reported financial results and business progress for the second quarter 2015.
-
11 August 2015
Tobira Therapeutics Reports Second Quarter 2015 Financial Results
Tobira Therapeutics, Inc. (TBRA), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel treatments for nonalcoholic steatohepatitis (NASH) and other serious immuno-inflammatory and fibrotic diseases, today reported business highlights and financial results for the second quarter of 2015.
-
11 August 2015
Epic Sciences announced today the publication of its research in the Journal of Circulating Biomarkers validating the company's no cell left behind™ platform. The data published demonstrate reproducible and linear assay performance in CTC enumeration as well as additional utility in downstream molecular characterization of single CTCs, including protein biomarker analysis and single cell genomics.
-
06 August 2015
Neothetics, Inc. (Nasdaq:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced the reaffirmation of all claims of two of its issued patents by the United States Patent and Trademark Office (USPTO) and termination of the reexamination challenges that were initiated by a third party.
-
04 August 2015
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2015 Financial Results
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update and announced its financial results for the second quarter ended June 30, 2015.
-
30 July 2015
Miramar® Labs, a global aesthetics company, today announced the release of the Optimized Treatment Protocol (OTP) in Europe and the Middle East. The new protocol, designed to increase patient satisfaction and reduce treatment times, should further expand the potential patient population for the miraDry® System which eliminates underarm sweat and odor glands.
-
23 July 2015
Miramar® Labs, an innovative global aesthetic company, announced today its miraDry® System received clearance from the U.S. Food & Drug Administration (FDA) for the treatment of unwanted underarm hair, and permanent reduction of underarm hair of all colors. This announcement establishes miraDry as the only technology FDA cleared for the treatment of underarm hair of all colors as well as the permanent reduction of underarm sweat.
-
16 July 2015
Miramar Labs® Announces Global Expansion of miraDry® System into Chinese Market
Global aesthetic company Miramar® Labs, Inc., announced today that it has received State Food & Drug Administration (SFDA) approval for the marketing and sale of the miraDry® system in the People's Republic of China. The approval follows US Food and Drug Administration (FDA) clearance of miraDry in January 2011and (CE) Mark approval in December 2013.
-
13 July 2015
Epic Sciences Appoints Dr. Greg Critchfield to Board of Directors
Epic Sciences, Inc. ("Epic Sciences"), a private biotech company that develops diagnostics to personalize the treatment and management of cancer, announced today the appointment of Gregory C. Critchfield, M.D. to Epic Sciences' board of directors. As current chairman, president and CEO of Sera Prognostics, Inc. and former president of Myriad Genetic Laboratories, Inc., Dr. Critchfield has more than 30 years of experience in the clinical pathology and diagnostics space.
All Portfolio
MEDIA CENTER
-
The RMI group has completed sertain projects
The RMI Group has exited from the capital of portfolio companies:
Marinus Pharmaceuticals, Inc.,
Syndax Pharmaceuticals, Inc.,
Atea Pharmaceuticals, Inc.